通过向SEC62 / TRPM4介导的NECSO,Cinobufagin克服了多发性骨髓瘤菌株的耐药性
Zhao Yin1, Guangchao Li2, Qi Zhong1
1The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong Province 510317, China.
概括
通过稳定TRPM4并诱导NECSO细胞死亡,Cinobufagin克服了多发性骨髓瘤中的博特佐米布耐药性. 这项研究确定了SEC62-TRPM4轴作为抗癌症的关键治疗点.
科学领域:
- 癌症学
- 细胞生物学
- 药理学
背景情况:
- 过载致死 (NECSO) 是一种新的细胞死亡途径,与癌症有关.
- TRPM4是唯一与NECSO相关的蛋白质,并且在抗博特佐米布多发性骨髓瘤 (MM) 中降低调控.
研究的目的:
- 调查巴在MM中克服博特佐米布耐药性的潜力.
- 阐明黄素的机制,重点是TRPM4和NECSO诱导.
主要方法:
- 使用了体外MM细胞系和体内异种移植模型.
- 对瘤增长,TRPM4表达和NECSO诱导进行了评估.
- 使用先进的分子技术研究了SEC62/TRPM4相互作用,无处不在和降解途径.
主要成果:
- 奇诺布法金抑制了抗博特佐米布的MM细胞增殖和瘤生长.
- 奇诺布法金增加了TRPM4,诱导了NECSO,并破坏了SEC62-TRPM4的相互作用.
- 干扰SEC62-TRPM4通过防止其蛋白质体降解来稳定TRPM4,从而逆转博特佐米布耐药性.
结论:
- TRPM4是一种可行的治疗对博尔特佐米布耐药性MM的标.
- 通过调节SEC62-TRPM4轴并诱导NECSO,Cinobufagin克服了抵抗.
- 在治疗耐药多发性骨髓瘤方面,Cinobufagin具有显著的治疗潜力.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K


